Deborah S. Mortensen

1.2k citations

28 papers · 785 indexed · h-index 12

Co-authors: Benita S. Katzenellenbogen John A. Katzenellenbogen Kathryn E. Carlson Alice L. Rodriguez Jun Sun Shaun R. Stauffer Zachary D. Aron Brian E. Fink
Topics: PI3K/AKT/mTOR signaling in cancer (11 papers)Estrogen and related hormone effects (5 papers)Synthesis and biological activity (4 papers)
Cited by: Toxicology Organic Chemistry Genetics
Journals: Journal of Clinical Oncology Blood Cancer
Partner nations: United States Switzerland Belgium

In The Last Decade

Deborah S. Mortensen

25 papers receiving 768 citations

Peers

Countries citing papers authored by Deborah S. Mortensen

Since Specialization

Citations

This map shows the geographic impact of Deborah S. Mortensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah S. Mortensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah S. Mortensen more than expected).

Fields of papers citing papers by Deborah S. Mortensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah S. Mortensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah S. Mortensen. The network helps show where Deborah S. Mortensen may publish in the future.

Co-authorship network of co-authors of Deborah S. Mortensen

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah S. Mortensen. A scholar is included among the top collaborators of Deborah S. Mortensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah S. Mortensen. Deborah S. Mortensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Recent advances in glutarimide chemistry for cereblon-mediated targeted protein degradation: developments in synthesis and diversification 2025 ·RSC Medicinal Chemistry ·(unknown),(unknown),Deborah S. Mortensen,Natalie Holmberg‐Douglas	1
2	Development of a Buchwald–Hartwig Amination for an Accelerated Library Synthesis of Cereblon Binders 2024 ·ACS Medicinal Chemistry Letters ·(unknown),(unknown),(unknown),J. Zhu,(unknown),Jianqing Li,Deborah S. Mortensen,Christoph W. Zapf,Gody Khambatta,(unknown),Natalie Holmberg‐Douglas	2
3	Discovery of an Azabicyclo[2.1.1]hexane Piperazinium Salt and Its Application in Medicinal Chemistry via a Rearrangement 2024 ·Organic Letters ·Chi He,(unknown),Hunter P. Shunatona,Jacob T. Edwards,Yixin Li,(unknown),Roger D. Sommer,Christoph W. Zapf,Deborah S. Mortensen	0
4	Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis 2021 ·Antimicrobial Agents and Chemotherapy ·Rokeya Tasneen,Deborah S. Mortensen,Paul J. Converse,Michael E. Urbanowski,Anna M. Upton,Nader Fotouhi,Eric L. Nuermberger,Natalie A. Hawryluk	13
5	Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis 2018 ·ACS Medicinal Chemistry Letters ·(unknown),(unknown),(unknown),(unknown),(unknown),Ronald Goldberg,Stacie Canan,Natalie A. Hawryluk,Deborah S. Mortensen,Vikram Khetani,Jerome B. Zeldis,John J. Siekierka,David P. Rotella	4
6	Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy 2014 ·Molecular Cancer Therapeutics ·Xi Chen,Elena Díaz‐Rodríguez,Enrique M. Ocio,Bruno Paiva,Deborah S. Mortensen,Antonia Lopez‐Girona,Rajesh Chopra,Jesús F. San Miguel,Atanasio Pandiella	8
7	306 CC-115 inhibits DNA damage and repair pathways in vitro 2014 ·European Journal of Cancer ·Toshiya Tsuji,Lisa M. Sapinoso,(unknown),Deborah S. Mortensen,Simiao Xu	1
8	523 Antitumor activity of mTOR kinase and DNA-PK inhibitor CC-115 in a mouse model of glioblastoma 2014 ·European Journal of Cancer ·Heather K. Raymon,(unknown),Jason D. Katz,Chunchun Zhao,Chia‐Wei Phan,Mehran F. Moghaddam,Kimberly E. Fultz,S Sankar,Deborah S. Mortensen,Rama Krishna Narla	1
9	459 Preclinical characterization of CC-115, a novel inhibitor of DNA-PK and mTOR kinase currently under clinical investigation 2014 ·European Journal of Cancer ·Deborah S. Mortensen,Kimberly E. Fultz,(unknown),(unknown),Matthew Hickman,Mahan Abbasian,Godrej Khambatta,Brian E. Cathers,Peter J. Worland,Mehran F. Moghaddam,Julius Apuy,Samantha J. Richardson,(unknown),(unknown),(unknown),Stacie Canan,Heather K. Raymon,Rama Krishna Narla,Shifang Peng,S Sankar	2
10	Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase 2013 ·Bioorganic & Medicinal Chemistry Letters ·Deborah S. Mortensen,John Sapienza,(unknown),(unknown),(unknown),(unknown),(unknown),Brandon Whitefield,Matthew Hickman,Gody Khambatta,(unknown),(unknown),(unknown),Jim Leisten,Rama Krishna Narla,Kimberly E. Fultz,Sabita Sankar	20
11	Abstract A165: Antitumor activity of mTOR kinase inhibitor CC-223 in a mouse model of prostate cancer. 2013 ·Molecular Cancer Therapeutics ·Rama Krishna Narla,(unknown),(unknown),Jason D. Katz,Julius Apuy,Mehran F. Moghaddam,Kimberly E. Fultz,Sabita Sankar,Deborah S. Mortensen,Heather K. Raymon	1
12	Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers. 2012 ·Journal of Clinical Oncology ·Kent C. Shih,Johanna C. Bendell,(unknown),Suzanne F. Jones,Robin Katie Kelley,Jeffrey R. Infante,Michael Korn,Kristen Hege,Rajesh Chopra,Shuichan Xu,Lilly Wong,Yong Liu,Deborah S. Mortensen,Pamela N. Münster	14
13	337 The Discovery and Preclinical Characterization of CC-223, a Novel mTOR Kinase Inhibitor Under Clinical Investigation 2012 ·European Journal of Cancer ·Deborah S. Mortensen,Kimberly E. Fultz,Matthew Hickman,Godrej Khambatta,Wei Xu,(unknown),Jianquan Zhao,Rama Krishna Narla,Heather K. Raymon,S Sankar	2
14	Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors 2011 ·Bioorganic & Medicinal Chemistry Letters ·Deborah S. Mortensen,(unknown),(unknown),(unknown),(unknown),Matthew Hickman,Gody Khambatta,(unknown),Kimberly E. Fultz,Sabita Sankar	24
15	P3‐259: Characterization of the pharmacokinetics, pharmacodynamics, and distribution of anti‐abeta antibody MABT5102A 2009 ·Alzheimer s & Dementia ·Deborah S. Mortensen,Rong Deng,Oskar Adolfsson,Stephen J. Tam,Kun Peng,Yanmei Lu,(unknown),(unknown),Kelly DuPree,Cinthia V. Pastuskovas,C. Andrew Boswell,(unknown),Guy Bormans,Suhasini Iyer,Leslie A. Khawli,Frank‐Peter Theil,Ryan J. Watts,Saileta Prabhu	1
16	A Novel mTOR Kinase Inhibitor Causes Growth Inhibition, Cell Cycle Arrest, Apoptosis and Autophagic Cell Death in Mantle Cell Lymphoma Cell Lines: A Distinct Profile from Rapamycin. 2008 ·Blood ·Weiming Xu,(unknown),Mercedes Delgado,(unknown),(unknown),Jennifer R. Riggs,John Sapienza,(unknown),(unknown),(unknown),Deborah S. Mortensen,Peter J. Worland,Sabita Sankar	1
17	Lead identification of a potent benzopyranone selective estrogen receptor modulator 2004 ·Bioorganic & Medicinal Chemistry Letters ·Jeffrey A. McKie,Shripad S. Bhagwat,Helen Brady,(unknown),(unknown),Matthew Hickman,(unknown),(unknown),(unknown),Deborah S. Mortensen,Normand Richard,John Sapienza,(unknown),Bernd Stein,May Kung Sutherland	33
18	Estrogenic diazenes: heterocyclic non-steroidal estrogens of unusual structure with selectivity for estrogen receptor subtypes 2003 ·Bioorganic & Medicinal Chemistry ·Usha Ghosh,Deshanie Ganessunker,(unknown),Kathryn E. Carlson,Deborah S. Mortensen,Benita S. Katzenellenbogen,John A. Katzenellenbogen	55
19	Furans with basic side chains: synthesis and biological evaluation of a novel series of antagonists with selectivity for the estrogen receptor alpha 2001 ·Bioorganic & Medicinal Chemistry Letters ·Deborah S. Mortensen,Alice L. Rodriguez,Jun Sun,Benita S. Katzenellenbogen,John A. Katzenellenbogen	36
20	Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens 1999 ·Chemistry & Biology ·Brian E. Fink,Deborah S. Mortensen,Shaun R. Stauffer,Zachary D. Aron,(unknown)	195

About Deborah S. Mortensen

Deborah S. Mortensen is a scholar working on Toxicology, Hematology and Oncology, having authored 28 papers that have together received 785 indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (11 papers), Estrogen and related hormone effects (5 papers) and Synthesis and biological activity (4 papers). The work is most often cited by research in Toxicology (81 citations), Organic Chemistry (452 citations) and Genetics (200 citations). Deborah S. Mortensen has collaborated with scholars based in United States, Switzerland and Belgium. Frequent co-authors include Benita S. Katzenellenbogen, John A. Katzenellenbogen, Kathryn E. Carlson, Alice L. Rodriguez, Jun Sun, Shaun R. Stauffer, Zachary D. Aron, Brian E. Fink, Shuichan Xu and Lilly Wong. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact